Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Diffuse Large B Cell Lymphoma
Related studies linked through entity extraction aliases.
Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE1
Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma
- Status
- UNKNOWN
- Phase
- N/A
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
- Status
- COMPLETED
- Phase
- PHASE2
Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+
- Status
- COMPLETED
- Phase
- PHASE3
Bortezomib Maintenance in High Risk DLBCL
- Status
- UNKNOWN
- Phase
- PHASE2
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
- Status
- TERMINATED
- Phase
- NA
Treatment of Diffuse Large B Cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE4
A Phase I Trial of AZD3965 in Patients With Advanced Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma
- Status
- COMPLETED
- Phase
- NA
Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE2
Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients
- Status
- COMPLETED
- Phase
- PHASE2
Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE3
Imexon for Relapsed Follicular and Aggressive Lymphomas
- Status
- COMPLETED
- Phase
- PHASE2